Please provide your email address to receive an email when new articles are posted on . Patients with MS had lower corneal nerve fiber density, corneal nerve branch density and corneal nerve fiber ...
Hosted on MSN
AI model redefines multiple sclerosis as a continuum with dynamic stages instead of subtypes
Multiple sclerosis (MS) has long been regarded as a disease with different subtypes such as "relapsing" or "progressive." An international study, published on August 20, 2025, in Nature Medicine under ...
Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...
Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.
MS involves both inflammation and neurodegeneration from the outset, not just one after the other. B-cells, a type of immune cell, are now understood to be critical drivers of the disease, a major ...
Oct 10 (Reuters) - Denali Therapeutics (DNLI.O), opens new tab said on Thursday its partner Sanofi (SASY.PA), opens new tab has discontinued a mid-stage study testing their experimental drug to treat ...
FRANKFURT, April 30 (Reuters) - Merck KGaA has started a mid-stage trial to evaluate the safety and efficacy of atacicept in patients with relapsing multiple sclerosis, the German drugs and chemicals ...
A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in ...
Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback